Mathematical Model Reveals How Copper and Zinc Drive Alzheimer’s Plaque Formation

Alzheimer’s disease remains one of the most formidable challenges in modern medicine, a condition that erodes memory and cognition while stubbornly resisting decades of therapeutic effort. Now, a team led by Shantia Yarahmadian, an associate professor in Mississippi State University’s Department of Mathematics and Statistics, is approaching the problem from an unexpected direction: not through a microscope or a petri dish, but through the language of differential equations. In a study published in the Bulletin of Mathematical Biology, Yarahmadian and collaborators constructed a mathematical framework that simulates how common metal ions, particularly copper and zinc, may steer the aggregation of amyloid-beta protein into the plaques that are a hallmark of the disease, and how two classes of potential therapies could intervene in that process.

The premise behind the work rests on a deceptively simple observation. Every biological phenomenon unfolds in physical space and time, involving continuous changes in shape, quantity and matter. Those changes can be described mathematically, and once they are, researchers gain a tool that observation alone cannot provide. “Every biological phenomenon occurs in the physical world—in space and time—and involves changes in shape, quantity and matter,” Yarahmadian explained. “Because of its abstract power, mathematics allows us to uncover patterns, test hypotheses and make predictions that may not be possible through observation alone.” In other words, a well-built model can compress years of trial-and-error experimentation into a set of equations whose behavior can be explored on a computer in hours.

The biological target of the model is amyloid-beta, a small protein fragment that, in a healthy brain, is produced and cleared in a carefully balanced cycle. In Alzheimer’s disease, that balance tips. Individual amyloid-beta peptides begin to misfold and cling to one another, first forming small soluble clusters called oligomers, then longer protofibrils, and finally the insoluble fibrillar plaques that accumulate between neurons. This aggregation cascade is not a single reaction but a branching network of processes, each with its own rate, and each potentially influenced by the chemical environment surrounding the protein. That complexity is precisely what makes the disease so difficult to study experimentally, and precisely where mathematical modeling earns its keep.

Metal ions enter the picture because of a long-standing and growing body of biochemical evidence that copper and zinc bind directly to amyloid-beta and can dramatically alter its aggregation behavior. Depending on concentration, oxidation state and conditions, these metals can accelerate the formation of aggregates, stabilize particular intermediate species, or change the morphology of the fibrils that ultimately form. Because copper and zinc are normally present in the brain and are involved in synaptic function, their interaction with amyloid-beta is not an exotic curiosity but a plausible contributor to disease progression. Capturing that interplay quantitatively, however, requires a model that tracks not only the protein’s aggregation states but also the binding and unbinding of metal ions at each stage—a considerable mathematical challenge.

Yarahmadian’s framework does exactly that. It simulates the chain of reactions through which metals such as copper and zinc may influence amyloid-beta aggregation and plaque formation, coupling the kinetics of protein clustering with the dynamics of metal-ion binding. Crucially, the model was designed to do more than describe the disease process; it also allows researchers to examine two potential therapeutic strategies for disrupting it. The first is chelation therapy, in which molecules would be deployed to sequester excess metal ions and strip them away from amyloid-beta, potentially slowing or reversing the aggregation they promote. The second involves inhibitory approaches that act directly on the aggregation pathway itself, interfering with the steps by which peptides assemble into larger structures. By adjusting parameters that represent these interventions, the model can explore how different treatment strategies might shift the balance of the system over time.

Building a model is one thing; proving that it means anything is another. A set of equations can be internally consistent and still bear no relationship to biological reality, so the team subjected their framework to a demanding test. They compared the model’s output against experimental data generated by atomic force microscopy, a technique capable of imaging aggregates at nanometer scale and revealing the size and structure of the microscopic clusters that amyloid-beta forms in the laboratory. This validation step is where many theoretical models falter, but here the results were encouraging: the model successfully reproduced the patterns observed in the experimental measurements.

That agreement matters more than it might first appear. It demonstrates that the model is not merely a theoretical calculation but a tool that can accurately predict real-world behavior, giving scientists greater confidence in understanding how aggregates form and, potentially, how they might be controlled. In practical terms, a validated model becomes a virtual laboratory. Researchers can ask questions that would be expensive, slow or ethically fraught to answer with real experiments: What happens if metal concentrations rise in a particular brain region? At what point in the aggregation cascade would a chelation therapy have the greatest effect? Which step in the reaction network is the most influential lever, and therefore the most promising drug target? The model cannot answer these questions definitively, but it can rank hypotheses and point experimentalists toward the tests most likely to be informative.

“Mathematics does not replace laboratory or clinical research; it complements it by helping us understand the larger system, identify the most influential mechanisms and guide future experiments,” Yarahmadian said. That division of labor is increasingly common across the life sciences. As biological datasets grow larger and the systems under study grow more intricate, the ability to formalize hypotheses mathematically and test them computationally has become a genuine partner to the bench and the clinic rather than an afterthought. In Alzheimer’s research specifically, where more than a hundred candidate drugs have failed in clinical trials over recent decades, tools that can narrow the search space before trials begin carry obvious value.

“What drew me to Alzheimer’s research is the combination of its profound human impact and its extraordinary biological complexity,” Yarahmadian said. “My goal is to use mathematical modeling to identify important mechanisms and generate insights that may help guide future experimental and therapeutic research.” The study, published on 20 August 2026 under the title describing metal-ion-mediated amyloid-beta aggregation and a mathematical model of chelation and inhibitory therapies, was classified as computational simulation and modeling, and its authors declared no conflicts of interest. The work builds on Yarahmadian’s broader research program into mathematical models of Alzheimer’s disease, positioning the Mississippi State group within a growing community of applied mathematicians tackling neurodegeneration.

The road from a validated model to a therapy is, of course, long. Mathematical frameworks do not shrink tumors or restore memories; their contribution is to sharpen the questions and reduce the guesswork. Yet in a field where the underlying mechanisms remain fiercely debated—where amyloid-beta’s role itself has been questioned after high-profile drug setbacks—quantitative tools that connect metal chemistry, protein aggregation and therapeutic intervention offer something rare: a way to see the system whole. If the model’s predictions continue to align with laboratory observations, the equations developed in Starkville may help decide where the next generation of Alzheimer’s experiments, and perhaps eventually treatments, should look. It would be a striking outcome if part of the answer to one of medicine’s hardest problems turned out to be written, at least in part, in mathematics.

Subject of Research: Mathematical modeling of metal-ion-mediated amyloid-beta aggregation and chelation therapies in Alzheimer's disease

Article Title: Solving Alzheimer’s with math? Researcher explores the possibilities

Article References: Solving Alzheimer’s with math? Researcher explores the possibilities. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Alzheimer's disease, mathematical modeling, amyloid-beta, copper, zinc, chelation therapy, plaque formation, computational biology, Mississippi State University, Bulletin of Mathematical Biology, atomic force microscopy, drug targets